Circumcision and/or vaccination against human papillomavirus in the male to prevent infection with human immunodeficiency virus: An early surrogate endpoint for the later prevention of penile, prostate, anal and oral cancer?

BJU International

Volumn 104, Issue 6, 2009, Pages 753-755

  Oliver, R T D ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ANUS CANCER; CIRCUMCISION; DISEASE ASSOCIATION; ENVIRONMENTAL SANITATION; FUNDING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOUTH CANCER; NOTE; PATIENT EDUCATION; PENIS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; UTERINE CERVIX CANCER; WART VIRUS;

CIRCUMCISION, MALE; FEMALE; HIV INFECTIONS; HUMANS; MALE; NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; VACCINATION;

EID: 69249139902     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08596.x     Document Type: Note

References (32)

1. Cameron DW, Simonsen JN, D'Costa LJ et al. Female to male transmission of human immunodeficiency virus type 1: risk factors for seroconversion in men. Lancet 1989 2 : 403 407
2. Oliver J, Oliver R, Ballard R. Influence of circumcision and sexual behaviour on PSA levels in patients attending a sexually transmitted disease (STD) clinic. Prostate Cancer Prostate Dis 2001 4 : 228 231
3. Oliver R, Oliver J, Ballard R. Male circumcision and HIV prevention. More studies need to be done before widespread circumcision is implemented. BMJ 2000 321 : 1468 1469
4. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005 2 : e298
5. Gray RH, Kigozi G, Serwadda D et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007 369 : 657 666
6. Bailey RC, Moses S, Parker CB et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007 369 : 643 656
7. Fitzpatrick JM. Editor's comment. BJU Int 2008 101 : i
8. Madsen BS, van den Brule AJ, Jensen HL, Wohlfahrt J, Frisch M. Risk factors for squamous cell carcinoma of the penis - population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev 2008 17 : 2683 2691
9. Gajalakshmi CK, Shanta V. Association between cervical and penile cancers in Madras. India Acta Oncol 1993 32 : 617 620
10. Barreto ML, Genser B, Strina A et al. Effect of city-wide sanitation programme on reduction in rate of childhood diarrhoea in northeast Brazil: assessment by two cohort studies. Lancet 2007 370 : 1622 1628
11. Gu F. Changing constituents of genitourinary cancer in recent 50 years in Beijing. Chin Med J 2003 116 : 1391 1393
12. Kumar B, Cordell KG, Lee JS et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 2008 26 : 3128 3137
13. Slater S, Oliver RT. Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy. Drugs Aging 2000 17 : 431 439
14. Oliver R. Medical Interventions relevant to management of early prostate cancer and its prevention: a new potential role for general practitioners, schools and works medical officers as well as STD and Infertility clinics. In Wallace DMA, Oliver RTD, eds, UK Key Advances in Clinical Practice Series the Effective Management of Prostate Cancer. London : Aesculapius Medical Press, 2002 : 117 138
15. Oliver T, Lorincz A, Cuzick J. Prostate cancer prevention by short-term anti-androgens: the rationale behind design of pilot studies. In Senn H-J, Kapp U, Otto F. Cancer Prevention II. Recent Results in Cancer Research, Vol I. Berlin : Springer Verlag, 2008 : 195 205
16. Iwasaka T, Hayashi Y, Yokoyama M, Hara K, Matsuo N, Sugimori H. 'Hit and run' oncogenesis by human papillomavirus type 18 DNA. Acta Obstet Gynecol Scand 1992 71 : 219 223
17. Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006 367 : 1247 55
18. Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007 369 : 1861 1868
19. Svare EI, Kjaer SK, Worm AM, Osterlind A, Meijer CJ, van den Brule AJ. Risk factors for genital HPV DNA in men resemble those found in women: a study of male attendees at a Danish STD clinic. Sex Transm Infect 2002 78 : 215 218
20. Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007 13 : 28 41
21. Kubba T. Human papillomavirus vaccination in the United Kingdom: what about boys? Reprod Health Matters 2008 16 : 97 103
22. Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 2006 24 : 2606 2611
23. D'Souza G, Kreimer AR, Viscidi R et al. Case-control study of human papillomavirus and oropharyngeal cancer. New Engl J Med 2007 356 : 1944 56
24. Marais DJ, Carrara H, Ramjee G, Kay P, Williamson AL. HIV-1 seroconversion promotes rapid changes in cervical human papillomavirus (HPV) prevalence and HPV-16 antibodies in female sex workers. J Med Virol 2009 81 : 203 210
25. Jong E, Mulder JW, van Gorp EC et al. The prevalence of human papillomavirus (HPV) infection in paired urine and cervical smear samples of HIV-infected women. J Clin Virol 2008 41 : 111 115
26. De Vuyst H, Lillo F, Broutet N, Smith JS. HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. Eur J Cancer Prev 2008 17 : 545 554
27. Morris BJ, Waskett J, Bailis SA. Case number and the financial impact of circumcision in reducing prostate cancer. BJU Int 2007 100 : 5 6
28. Dillner J, Knekt P, Boman J et al. Sero-epidemiological association between human papillomavirus infection and risk of prostate cancer. Int J Cancer 1998 75 : 564 567 (Pubitemid 28094102)
29. Korodi Z, Dillner J, Jellum E et al. Human papillomavirus 16, 18, and 33 infections and risk of prostate cancer: a Nordic nested case-control study. Cancer Epidemiol Biomarkers Prev 2005 14 : 2952 2955
30. Oliver R. Though HIV is the main cause of AIDS, other factors play a role. Nature 2000 406 : 673
31. Dunkle KL, Jewkes RK, Brown HC, Gray GE, McIntryre JA, Harlow SD. Gender-based violence, relationship power, and risk of HIV infection in women attending antenatal clinics in South Africa. Lancet 2004 363 : 1415 1421
32. Donovan J, Hamdy F, Neal D et al. Prostate testing for cancer and treatment (protect) feasibility study. Health Technol Assess 2003 7 : 1 88